BNB Plus Corp Secures European Patent to Accelerate Global mRNA Production

2026-03-19 companies

Munich, Wednesday, 18 March 2026.
Securing critical intellectual property rights through 2040, BNB Plus Corp’s new European patent empowers its advanced platform to deliver faster, cleaner mRNA production for the expanding biotherapeutics market.

Expanding the Intellectual Property Moat

On March 18, 2026, BNB Plus Corp. (NASDAQ: BNBX) announced that the European Patent Office (EPO) officially granted a patent to its biopharmaceutical subsidiary, LineaRx, Inc. [1][3][6]. The patent, designated as European Patent Application No.: 21882234.4 (EP4232569A1), is entitled “Compositions and Methods for RNA Synthesis” [1][2][3]. This regulatory milestone follows a corresponding U.S. patent that was awarded to the company in 2024 [1][2][5]. The newly issued European patent specifically covers the composition of LineaRx’s chemically modified RNA polymerase enzyme, which is commercially branded as Linea RNAP [1][3][4]. Moving forward, BNB Plus Corp. plans to validate the patent across key European markets, a strategic maneuver designed to secure intellectual property protection through at least the year 2040 [1][2][5]. [alert! ‘The exact status of the European market validations remains pending, as the company has only announced its plans to validate the patent without confirming completion.’]

The Technological Edge of Linea IVT

Linea RNAP serves as the foundational core of the Linea IVT (in vitro transcription) platform, an advanced system engineered to optimize mRNA production [1][2][4]. A critical advantage of this platform is its ability to eliminate the need for plasmid DNA as a starting material [2][3][4]. Consequently, the Linea IVT workflow significantly prevents or reduces double-stranded RNA (dsRNA) contamination, which remains a persistent and costly challenge in conventional mRNA manufacturing [2][3][4]. By simplifying the production workflow, the platform enables manufacturers to produce higher-quality mRNA and self-amplifying mRNA (sa-mRNA) at an accelerated pace [2][4][5].

Strategic Leadership and Market Positioning

The patent grant represents a critical step for the company’s commercial ambitions. Clay Shorrock, CEO and President of BNB Plus Corp., stated that securing patent protection in Europe is a “significant milestone” in establishing a global intellectual property portfolio [1][3][5]. Shorrock emphasized that the European grant, paired with the existing U.S. patent, positions the company to assist mRNA manufacturers in producing therapeutics more efficiently while opening avenues for intellectual property monetization in the rapidly growing European biotherapeutics market [1][4][5]. The executive team, which includes Chief Financial Officer Beth Jantzen, is further bolstered by a strategic advisory board featuring notable figures such as Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital [5].

Sources

Biotechnology Patents